The Emergence of Novel SARS-CoV-2 (COVID-19) a Triple Reassortant Corona Virus Immunogenicity and Reactogenicity in Human LE01-LE04
Dr. Debasish Pradhan,
Department of Pharmaceutical Sciences, Utkal University, Bhubaneswar, Odisha, India.
Presently, the emergence of a novel human corona virus, Severe Acute Respiratory Syndrome (SARS)-CoV-2, has lead to a global health concern. It causes severe respiratory tract infections in humans. WHO on March 11, 2020, declared COVID-19 (Corona Virus) as a pandemic. There have been more than 3,842,000 confirmed COVID-19 cases in the world. The reports have shown sharp increase in the number of infections reported in recent days from Italy, Iran, South Korea, Spain, Germany, United States, and other parts of the world, with the most dramatic increase recorded in China where more than 80,000 cases were reported in a very short duration. Neither potential medication nor vaccines are available in the market and the virus can manifest itself both symptomatically and asymptomatically in the human system.